We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
-2.2%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$78.1B
AUM Growth
-$1.98B
(-2.5%)
Cap. Flow
-$7.02B
Cap. Flow
% of AUM
-8.99%
Top 10 Holdings %
Top 10 Hldgs %
28.7%
Holding
1,440
New
63
Increased
853
Reduced
452
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kinross Gold
KGC
|
+$440M |
| 2 |
C.H. Robinson
CHRW
|
+$323M |
| 3 |
Advanced Micro Devices
AMD
|
+$322M |
| 4 |
Tyler Technologies
TYL
|
+$317M |
| 5 |
Merck
MRK
|
+$286M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$11.9B |
| 2 |
NVIDIA
NVDA
|
+$409M |
| 3 |
Autodesk
ADSK
|
+$261M |
| 4 |
Salesforce
CRM
|
+$258M |
| 5 |
Clorox
CLX
|
+$238M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.82% |
| 2 | Materials | 22.17% |
| 3 | Healthcare | 8.64% |
| 4 | Industrials | 7.37% |
| 5 | Financials | 5.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Guardant Health
GH
$21.3B
| $88K | ﹤0.01% |
2,887
+929
| +47% | +$26.1K |
|
1277
Hims & Hers Health
HIMS
$7.13B
| $86K | ﹤0.01% |
3,562
-274
| -7% | -$6.79K |
|
1278
Ally Financial
ALLY
$13.4B
| $85K | ﹤0.01% |
+2,372
| New | +$86.1K |
|
1279
Onto Innovation
ONTO
$13.4B
| $83K | ﹤0.01% |
500
-86
| -15% | -$15.7K |
|
1280
Globant
GLOB
$1.6B
| $81K | ﹤0.01% |
379
-19
| -5% | -$4.14K |
|
1281
ATS Corp
ATS
$2.69B
| $76K | ﹤0.01% |
2,483
-1,747
| -41% | -$53K |
|
1282
Ultragenyx Pharmaceutical
RARE
$2.46B
| $74K | ﹤0.01% |
1,760
+273
| +18% | +$13.5K |
|
1283
Herbalife
HLF
$1.32B
| $70K | ﹤0.01% |
10,526
+5,524
| +110% | +$41K |
|
1284
Fomento Económico Mexicano
FMX
$42.8B
| $68K | ﹤0.01% |
801
-1
| -0.1% | -$93 |
|
1285
Ouster
OUST
$2.86B
| $68K | ﹤0.01% |
5,546
-1,718
| -24% | -$15.1K |
|
1286
Hain Celestial
HAIN
$45.5M
| $66K | ﹤0.01% |
10,805
+3,554
| +49% | +$28.4K |
|
|
CVGW
1287
DELISTED
Calavo Growers
CVGW
| $65K | ﹤0.01% |
2,542
+1,039
| +69% | +$28.3K |
|
1288
iShares 7-10 Year Treasury Bond ETF
IEF
$47.1B
| $65K | ﹤0.01% |
706
+340
| +93% | +$32.1K |
|
1289
Limoneira
LMNR
$239M
| $63K | ﹤0.01% |
2,581
+1,127
| +78% | +$30.1K |
|
1290
Symbotic
SYM
$5.83B
| $62K | ﹤0.01% |
2,601
-896
| -26% | -$25.5K |
|
1291
LeMaitre Vascular
LMAT
$2.37B
| $61K | ﹤0.01% |
664
-197
| -23% | -$18.9K |
|
1292
Seneca Foods Class A
SENEA
$1.15B
| $58K | ﹤0.01% |
729
+309
| +74% | +$21.3K |
|
1293
Arrowhead Research
ARWR
$12.1B
| $56K | ﹤0.01% |
2,978
+1,250
| +72% | +$25.7K |
|
1294
Southwest Gas
SWX
$6.5B
| $51K | ﹤0.01% |
726
+30
| +4% | +$2.23K |
|
1295
iRhythm Holdings
IRTC
$4.1B
| $50K | ﹤0.01% |
554
+162
| +41% | +$12.7K |
|
1296
Itron
ITRI
$4.42B
| $50K | ﹤0.01% |
456
+11
| +2% | +$1.23K |
|
1297
New Jersey Resources
NJR
$5.86B
| $48K | ﹤0.01% |
1,032
-79
| -7% | -$3.75K |
|
1298
Laureate Education
LAUR
$5.18B
| $45K | ﹤0.01% |
2,455
+196
| +9% | +$3.44K |
|
1299
Omnicell
OMCL
$1.71B
| $44K | ﹤0.01% |
985
+315
| +47% | +$14.1K |
|
|
PINC
1300
DELISTED
Premier
PINC
| $43K | ﹤0.01% |
2,041
+446
| +28% | +$9.46K |
|
Similar funds
VanEck Associates's Q4 2024 Portfolio in Review
As of Q4 2024, VanEck Associates held 1,440 positions worth $78.1B, down 2.5% from $80.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
VanEck Associates withdrew a net $7.02B in Q4 2024, closing 54 positions and reducing 452 holdings. Its most notable exit was Bank of New York Mellon, an estimated $9.49M position sold in full.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 41% a quarter earlier, followed by Materials and Healthcare.
Against the trend, VanEck Associates opened a new position in Boeing Co 6.00% Series A Preferred Stock worth $251M.
- VanEck Associates's largest Q4 2024 buy was Boeing Co 6.00% Series A Preferred Stock: 4,123,397 shares worth $251M.
- VanEck Associates added most to Kinross Gold in Q4 2024, an estimated $440M increase.
- VanEck Associates's biggest Q4 2024 reduction was Lam Research, cutting an estimated $11.9B.
- VanEck Associates fully exited Bank of New York Mellon in Q4 2024, selling an estimated $9.49M.
- VanEck Associates's ten largest holdings make up 29% of its $78.1B portfolio in Q4 2024.
- VanEck Associates opened 63 new positions and closed 54 in Q4 2024.
- VanEck Associates's portfolio value fell 2.5% quarter-over-quarter to $78.1B.
Based on VanEck Associates's 13F filing for Q4 2024, filed 29 Jan 2025.